###### Strengths and limitations of this study

-   Allometric dose of miltefosine in treating PKDL is initiated first through this study.

-   Development of picture-based scoring system is also initiated first through this study.

-   Risk factor analysis among children with PKDL is another important strength of this study.

-   Subjective error during scoring may happen.

-   There is no gold standard to validate the scoring system.

Introduction {#s1}
============

Post-kala-azar dermal leishmaniasis (PKDL) is a skin disorder that mostly develops following treatment for visceral leishmaniasis (VL).[@R1] Other than having skin lesions, patients with PKDL are healthy, but they are unfortunately stigmatised in the society---especially girls and women.[@R2] The *Leishmania donovani* parasite, harboured in skin lesions of PKDL, can initiate an epidemic outbreak of VL in the community by transmitting the parasite through sandfly bites.[@R2] Consequently, it is of the utmost importance to actively search for patients with PKDL and determine their safe and effective treatment, to control VL in the Indian subcontinent, including Bangladesh.[@R2]

Significance of a trial with miltefosine {#s1a}
----------------------------------------

Until recently, stibogluconate (SSG) was the only therapeutic option for PKDL.[@R2] [@R3] This involves intramuscular injections of SSG (20 mg/kg/day) for 20 consecutive days per month, for 6 months (120 injections in total). SSG injections are very painful, and serious adverse events (SAEs) including death due to sudden cardiac arrest have been observed.[@R4] As such, patients with PKDL often do not seek medical care, and frequently there low treatment compliance reported when receiving SSG treatment.[@R7] Thus, a safe, effective and affordable treatment regimen with shorter duration compared with that with conventional SSG therapy for PKDL is urgently needed.

Complementary drugs for PKDL include miltefosine (MF), amphotericin B, liposomal amphotericin B and immunotherapy in combination with SSG. One study in India compared the efficacy of amphotericin B with SSG and found that amphotericin B was superior to SSG; however, its nephrotoxicity and high price limited its use.[@R8] A substitute for SSG therapy is the combination of SSG with immunotherapy. So far, only one study reported a high cure rate (87%) of PKDL with immunotherapy in Sudan,[@R9] involving SSG coupled with the first-generation vaccine (alum-precipitate autoclaved *Leishmania major* plus BCG). Any risk of adverse events from SSG and potentially from autoclaved *L. major* cannot be disregarded. On the basis of a literature review, we found that 12 weeks of MF monotherapy is the best possible alternative existing to the 120 SSG injections for PKDL treatment.[@R10] However, all the studies reported a very small number of PKDL cases. Unfortunately, information regarding either the safety and efficacy of 12 weeks of MF treatment of children with PKDL or the pharmacokinetics of MF in children was not available. It was established that exposure to MF in children with VL was less to oral MF at a conventional dose of 2.5 mg/kg/day. Thus, allometric dosing of MF has now been recommended by experts.[@R19] A study is therefore urgently needed to evaluate the efficacy and safety of MF treatment at an allometric daily dose for 12 weeks in children with PKDL.

Relevance of host, environmental and nutritional risk factor analyses {#s1b}
---------------------------------------------------------------------

PKDL is more common in Bangladesh among treated VL patients than in India and Nepal.[@R20] The reasons for this remain to be elucidated. Perhaps genetic susceptibility, as in Sudan, nutritional status of the host and environmental factors play roles in the development of PKDL in Bangladesh.[@R21] A study in Sudan indicated that interleukin 10 (IL-10) and interferon-γ (IFN-γ) gene polymorphisms were associated with PKDL development.[@R1] [@R22] [@R23] This immune polymorphism resulted in an inefficient Th~1~ immune response to clear the infection with *L. donovani.*[@R24] Moreover, environmental factors such as chronic exposure to arsenic may also influence the development of PKDL. Arsenic exposure has been shown to negatively influence the innate and adaptive immune responses to infections.[@R25] Therefore, it is possible that a higher exposure to arsenic would favour PKDL development by decreasing the efficacy of drugs in maintaining an adequate Th~1~ response required to effectively clear the *L. donovani* infection. Exposure to arsenic, a global health problem, can occur from drinking water sourced from the ground.[@R26] [@R27] Bangladesh appears to be the most afflicted, with 59 of 64 districts affected by varying degrees of ground water contamination, including the Mymensingh district.[@R27] Furthermore, arsenic exposure was also associated with depressed serum levels of antioxidants such as vitamins E, A and D, and of serum cholesterol.[@R28] [@R29] Low levels of serum cholesterol have indeed been linked with a higher risk for VL.[@R29] In other words, vitamin E is necessary for optimum innate and adaptive immune responses to infection, and to maintain the normal immune function of the skin.[@R30] Consequently, improving the treatment efficacy for leprosy with antioxidant(s) supplementation had been proposed.[@R31] [@R32] Therefore, decreased serum levels of vitamin E due to nutritional deficiency and/or arsenic exposure, and arsenic itself may independently play important roles in the pathogenesis of PKDL. That is why, here we also propose to investigate the association of serum vitamins E, A and D, zinc and arsenic exposure with PKDL.

Methods/design {#s2}
==============

The study was designed to test the following hypotheses:

Primary hypothesis: Oral MF treatment of children with PKDL at allometric daily dose (based on body weight and height) for 12 weeks is safe, with a cure rate of ≥95%.

Secondary hypothesis: Development of PKDL in children and adolescents is genetically predisposed and is associated with IL-10 and IFN-γ gene polymorphisms causing high and low serum level of IL-10 and IFN-γ, respectively.Nutritional and environmental factors such as low serum vitamins E, A and D, zinc and arsenic exposure are associated with PKDL development.

Experimental design {#s2a}
-------------------

The study includes a cross-sectional survey of children treated for VL in the past, followed by an open clinical trial of 12 weeks of oral MF treatment for parasitologically confirmed children with PKDL, and their 12 months of follow-up and a simultaneous case--control study for PKDL risk factors.

Study area and population {#s2b}
-------------------------

The study will be carried out in the district of Mymensingh, Bangladesh. VL is prevalent in 45 districts of Bangladesh, with Mymensingh being the most VL endemic. About 50--60% of total cases of VL in Bangladesh were reported from Mymensingh; 5 of the 12 upazilas (subdistricts) are endemic for VL.

Cross-sectional survey {#s2c}
----------------------

Trained senior field research assistants (SFRAs) will collect the address details of children previously treated for VL, in the upazila hospitals of Muktagacha, Trishal, Fulbaria, Bhaluka and Gafforgaon. Following the collected information, they will visit the households of the children, and with informed written voluntary consent from parent/guardian of the child, SFRA will screen the child for suspected PKDL. Subsequently, the suspected cases will be referred to study clinics for confirmation and enrolment.

Enrolment for the trial (cases) {#s2d}
-------------------------------

After confirmation of the diagnosis of PKDL, the child will be enrolled in the trial against study inclusion or exclusion criteria ([table 1](#BMJOPEN2015010050TB1){ref-type="table"}) and will receive treatment with MF for 12 weeks at allometric daily dose ([table 2](#BMJOPEN2015010050TB2){ref-type="table"}).

###### 

Study enrolment criteria

  Case                                                                                          Control                                                                                                                          
  --------------------------------------------------------------------------------------------- ---------------------------------- --------------------------------------------------------------------------------------------- -------------------------------------
  Age \>2 years and \<18 years                                                                  Do not fulfil inclusion criteria   Age \>2 years and \<18 years                                                                  Do not fulfil inclusion criteria
  Treated for VL in the past                                                                    Lesions with mucosal involvement   Treated for VL in the past                                                                    Serious concomitant illness
  Currently with skin lesions such as PKDL                                                      Serious concomitant illness        Currently with no skin lesions such as PKDL                                                   Cannot be followed up
  Positive for *Leishmania donovani* bodies by microscopy and or DNA by qPCR in their skin      Cannot be followed up              Clinically healthy and free from other chronic illness                                        Controls with PKDL during follow-up
  Clinically healthy and free from other chronic illness                                        Female married adolescent          Received no treatment for PKDL                                                                
  Received no treatment for PKDL in the last 6 months                                                                              Normal hepatic, renal and haematological functions                                            
  Normal hepatic, renal and haematological functions                                                                               Parent/guardian provided informed voluntary written consent for his/her child participation   
  Parent/guardian provided informed voluntary written consent for his/her child participation                                                                                                                                    

PKDL, post-kala-azar dermal leishmaniasis; qPCR, quantitative PCR; VL, visceral leishmaniasis.

###### 

Allometric dose chart[@R19]

  Weight (kg)   Total daily allometric miltefosine dose (mg) for patient of indicated height (cm)                                                            
  ------------- ----------------------------------------------------------------------------------- ---- ---- ---- ----- ----- ----- ----- ----- ----- ----- -----
  Male                                                                                                                                                       
   9            30                                                                                  40   40   40   40                                        
   12           40                                                                                  40   40   50   50    50                                  
   15                                                                                               40   50   60   60    60                                  
   20                                                                                                    50   60   60    70    70    70                      
   25                                                                                                         60   70    70    80    80    80                
   30                                                                                                              80    80    90    90    90    100         
   35                                                                                                              80    90    90    100   100   100   110   
   40                                                                                                              80    90    100   100   110   110   120   130
   45                                                                                                              90    90    100   110   110   120   130   130
   50                                                                                                              90    100   100   110   120   120   130   140
   55                                                                                                              90    100   110   120   120   130   140   150
   60                                                                                                              90    100   110   120   130   130   150   150
   65                                                                                                              100   110   110   120   130   140   150   150
   75                                                                                                              100   110   120   130   140   140   150   150
   85                                                                                                              100   110   120   130   140   150   150   150
  Female                                                                                                                                                     
   9            30                                                                                  40   40   40   40                                        
   12           40                                                                                  40   40   50   50    50                                  
   15                                                                                               40   50   60   60    60                                  
   20                                                                                                    50   60   60    70    70    70                      
   25                                                                                                         60   70    70    80    80    80                
   30                                                                                                              80    80    90    90    90    100         
   35                                                                                                              80    90    90    100   100   100   110   
   40                                                                                                              80    90    100   100   110   110   120   130
   45                                                                                                              90    90    100   110   110   120   130   130
   50                                                                                                              90    100   100   110   120   120   130   140
   55                                                                                                              90    100   110   120   120   130   140   150
   60                                                                                                              90    100   110   120   130   130   150   150
   65                                                                                                              100   110   110   120   130   140   150   150
   75                                                                                                              100   110   120   130   140   140   150   150
   85                                                                                                              100   110   120   130   140   150   150   150

A dose of 150 mg is currently considered as maximum tolerable dose.

Study medication, adverse events and management {#s2e}
-----------------------------------------------

Children with PKDL in the trial will be treated with oral MF, obtained from the company, Paladin Labs (Canada). The daily total dose of MF will be based on allometric calculation and rounded to the nearest 10 mg (the smallest commercially available capsule of MF) ([table 2](#BMJOPEN2015010050TB2){ref-type="table"}). The duration of treatment will be 12 weeks. The trade name of the drug is Impavido, earlier produced by Zentaris (Germany), and now by the Paladin Labs (Canada). Impavido is available in 10 and 50 mg capsule formulation. Direct observed treatment (DOT) will be conducted to ensure 100% treatment compliance through study health workers. A treatment card will be provided through which information about pharmacovigilance will be collected. Parents or guardians of the child will be informed about the common adverse events of MF treatment, and they as well as the DOT providers will be educated in management of these common adverse events which usually includes oral rehydration in case of vomiting and diarrhoea. Each child will also be followed over cellphone on a daily basis by the study SFRA. In case of adverse events, which cannot be managed by parents, guardians or DOT providers, the child will be brought to the study clinic for examination and management by the study team and by the hospital doctor in need. In case of SAE, the child will be taken care of in the upazila hospital first and subsequently referred to the Mymensingh Medical College Hospital, if needed. Adverse events will be graded following the Common Terminology Criteria for Adverse Events (CTCAE V.4.0, 2010) of the National Institutes of Health, USA.[@R33]

Follow-up and cure assessment in cases {#s2f}
--------------------------------------

Children in the trial will be monitored for 12 months after completion of treatment, and periodic assessments every 3 months regarding response to treatment will be performed using the proposed scoring method. To date, there is no standardised scoring method for the affected area of skin by the lesions of PKDL. In the current proposal, we aim to use a new method to this end ([figure 1](#BMJOPEN2015010050F1){ref-type="fig"}). Using the following picture ([figure 1](#BMJOPEN2015010050F1){ref-type="fig"}), skin lesions will be plotted in squares of the picture. The total number of squares containing lesions will be counted before and after treatment during the 12-month follow-up. The percentage of skin lesions cured by the treatment will be calculated as follows: total number of squares free from lesions after treatment×100/total number of squares affected by the lesions at baseline.

![Scoring system.](bmjopen2015010050f01){#BMJOPEN2015010050F1}

The response to treatment will be evaluated clinically through assessment of scores for affected surface of skin at every 3 months following treatment. However, cure assessments will be done at 12 months only. Two end points will be used for cure assessment: (1) at \>90% resolution of skin lesions plus a negative PCR assay for skin and peripheral blood buffy coat; (2) complete resolution of skin lesions.

Enrolment and follow-up of controls {#s2g}
-----------------------------------

### Enrolment {#s2g1}

The specific inclusion and exclusion criteria ([table 1](#BMJOPEN2015010050TB1){ref-type="table"}) will be used to register children as control patients in the case--control study.

### Follow-up of controls {#s2g2}

These children will be monitored for 15 months to match patients with PKDL who will be in the study for a total period of 15 months (3 months of treatment+12 months of follow-up after treatment). Each control will be assessed for signs and symptoms of PKDL every 3 months during follow-up. If any is found with suspected PKDL, then they will undergo parasitological confirmation. If a diagnosis of PKDL is confirmed, the individual will be excluded from the study as control, and instead, treated with MF, and will be referred to the hospital for further management as per national guideline. Stepwise activity is presented in [figure 2](#BMJOPEN2015010050F2){ref-type="fig"}.

![Enrolment and follow-up of study children. LD, *Leishmania donovani*; PKDL, post-kala-azar dermal leishmaniasis; qPCR, quantitative PCR; VL, visceral leishmaniasis.](bmjopen2015010050f02){#BMJOPEN2015010050F2}

Clinical specimen collection and laboratory methods {#s2h}
---------------------------------------------------

### Clinical specimen collection {#s2h1}

Venous blood (5 mL) from forearm, urine (10 mL) and hair (1 g) specimens will be collected from cases before and after treatment, and from controls at enrolment (baseline) only. Collected blood specimens will be analysed for haematological, hepatic and renal functions. DNA isolated from collected blood will be tested for *L. donovani* DNA, IFN-γ and IL-10 gene polymorphisms. The serum levels of α-tocopherol, albumin, cholesterol, serum glutamate-pyruvate transaminase (SGPT) and creatinine, and electrolytes (Na, K and Cl) will be measured before and after treatment in cases and once in control during enrolment. The concentration of arsenic will be measured in hair and urine specimens.

### Laboratory methods {#s2h2}

Haematological tests will be performed using an AutoAnalyzer and will include complete cell count, haemoglobin and erythrocyte sedimentation rate (ESR). Biochemical tests will include those for SGPT (hepatic function), serum creatinine (renal function) and serum levels of cholesterol, albumin and electrolytes (Na, K and Cl). All these tests will be performed in a certified laboratory in Mymensingh, or in ICDDR,B clinical pathology lab in Dhaka. Skin specimens will be taken by skin scraping for detection of fungal infection by potassium hydroxide (KOH) testing and by skin punch biopsy for microscopic (1000 fields will be examined for Leishman-Donovan (LD) amastigote) and quantitative PCR (qPCR) examination. The biopsy material will be prepared for Giemsa staining on glass microscope slides (air-dried, fixed with absolute methanol and finally stained by Giemsa). The remaining biopsy material will be kept in a normal saline solution until DNA isolation (Qiagen kit). Microscopic examination for *L. donovani* bodies and detection of *L. donovani* DNA by qPCR in the skin specimens will be performed in the parasitology laboratory of ICDDR,B. Serum α-tocopherol, vitamin A and Zn will be measured in the nutritional biochemistry laboratory of ICDDR,B by high-performance liquid chromatography (HPLC) (vitamins E and A) and atomic absorption (Zn). The concentrations of arsenic in hair and urine will be measured by hydride generation atomic absorption spectrometry as well. *L. donovani* DNA in the peripheral blood buffy coat will be detected by qPCR.[@R34] In this study, our targeted single-nucleotide polymorphic (SNP) variant site of IFN-γ will be +874T/A, which resides in the first intron of IFN-γ gene, and for IL-10 the SNP site will be −1082G/A, one of the three SNPs in their promoter region of IL-10 gene. Both SNPs will be typed using amplification refractory mutation system PCR (ARMS PCR) method.[@R35] [@R36] The serum level of cytokines will be determined by Luminex assays. SNP −1082G/A and +874T/A are related to increased secretion of IL-10 (GG genotype) and lower secretion of IFN-γ, respectively.[@R36] Specific polymorphisms and primers will be used ([table 3](#BMJOPEN2015010050TB3){ref-type="table"}).

###### 

Characteristics of IL-10 and IFN-γ polymorphism and primer sequences for amplification refractory mutation system PCR[@R34]

  Polymorphism location allele   Product size (bp)            Sequence           
  ------------------------------ ---------------------------- ------------------ ---------------------------------
  IL-10 (−1082 bp locus)         Generic primer (antisense)                      5′-cagcccttccattttactttc-3′
  IL-10\*G                       550                          Primer G (sense)   5′-tactaaggcttctttgggag-3′
  IL-10\*A                       550                          Primer A (sense)   5′-ctactaaggcttctttgggaa-3′
  IFN-γ (intron 1)               Generic primer (antisense)                      5′-tcaacaaagctgatactcca-3′
  IFN-γ \*A                      261                          Primer A (sense)   5′-ttcttacaacacaaaatcaaatca-3′
  IFN-γ \*T                      261                          Primer T (sense)   5′-ttcttacaacacaaaatcaaatct-3′
  Internal control               426                          Primer 1 (sense)   5′-gccttccaaccattccctta-3′
                                                              Primer 2 (sense)   5′-tcacggatttctgttgttgtgtttc-3′

Bp, base pair; IFN-γ, interferon γ; IL-10, interleukin 10.

Calculation of sample size {#s2i}
--------------------------

Sample size trial: based on an expected 95% cure rate, a sample size of 73 children with PKDL would produce a two-sided 95% CI with an estimated precision of 5%. Allowing for an attrition rate of 10%, the final sample size would be 80 children in each group, for a total sample size of 160.

Sample size for case--control study: we are interested in identifying risk factors which eventually can be candidates for a predictive marker for PKDL. Considering this, we hypothesise that children with PKDL will have a prevalence of risk factor(s) (IFN-γ gene polymorphism/IL-10 gene polymorphism/vitamin E deficiency/higher values of arsenic in hair or urine 80% and in controls 20%). Considering α of 5% and study power of 90%, a sample size of 16 in each group will be needed. Therefore, a sample size of 80 in each group will be sufficient even an attrition rate is 10%.

Statistical analysis {#s2j}
--------------------

Information from the survey and clinical and laboratory information at baseline and during follow-up will be computerised using an MS Access database program. All information will be verified by the study research officer and research investigator prior to data entry. Descriptive and analytical statistical methods will be used. Statistically significant differences between means will be compared by parametric (t test, analysis of variance (ANOVA)) or non-parametric (non-parametric paired test or Kruskal-Wallis) tests, where applicable. Comparison between proportions will be assessed by χ^2^ test with Fisher\'s exact correction, where applicable. Intention-to-treat (ITT) as well as per-protocol (PP) analyses will be performed for assessment of initial and definitive cure with 95% CI limits, according to Clopper and Pearson. Safety analyses will include a calculation of incidence for all adverse events. Scoring will also be calculated for cure analysis. Depending on the distribution and nature of the data, bivariate as well as multivariate analysis using logistic regression, mixed-effects model or generalized estimating equation (GEE) will be used to determine risk analysis.

### Quality assurance and control {#s2j1}

The study team will be trained in good clinical practice by a WHO-certified external clinical trial monitor during the kick-off meeting of the study. The monitor will visit after the enrolment of first 30 participants and then on completion of treatment. The final study\'s closing visit will be expected at the end of the study. All clinical laboratory tests will be conducted in an International Organization for Standardization (ISO)-certified laboratory of ICDDR,B. The nutrient and arsenic measurements will be performed in the internationally recognised Nutritional Biochemistry Lab of ICDDR,B, where methods for determination of vitamins A and E and Zn are ISO certified. The qPCR protocol for determination of *L. donovani* in different specimens will be obtained from the Infectious Disease Research Institute, Seattle, USA, and will be validated in the ICDDR,B Parasitology Laboratory. The PCR methods for targeted SNP analysis will be carried out in the ICDDR,B Parasitology Laboratory, which has extensive expertise with similar tests in other infectious diseases. Experts from the University of Nagasaki, Japan, will verify these findings.

Ethical issue {#s2k}
-------------

The proposed study will be conducted according to the principles of the Declaration of Helsinki (2008). The study physician will obtain informed written consent from all participants, or their legal representatives (LRs), if they lack capacity before or at the time of enrolment. Patients (or their LRs) are free to withdraw from the study at any time, as this will be explicitly indicated on the patient information sheet. The data collected for the study will be identified by a code and only the study physician and researchers will be able to link those data with patients and their clinical history. Consequently, the patient\'s identity will not be revealed to any other person, except in cases of medical emergency or if required to do so by law. Access to patient information will be restricted to the study doctor and collaborators, the health authorities from the Government of Bangladesh, the Clinical Research Ethics Committee and personnel authorised by the sponsor when they need to check the data and procedures used in the study, but always maintaining the confidentiality of the said information in accordance with current legislation. The trial protocol, the informed consent form and the information sheet received Research Ethics Committee approval in June 2014.

### Publication plan {#s2k1}

The research team plans to publish the study results in a peer-reviewed journal within 12 months of the completion of the study. Results will be analysed and reported in accordance with data analysis plan.

Discussion {#s3}
==========

Since most of the patients with PKDL are children and complete treatment coverage is essential to terminate the root of disease transmission, a safe, effective and user-friendly treatment option should be identified for children with PKDL. It is also critical to pinpoint the contributing factors to PKDL in order to devise an effective preventive policy.

Through this study, we aim to find out the efficacy and safety profiles of 12 weeks of MF therapy at allometric dose in children with PKDL. If we find this effective and safe, we will then recommend to the national elimination programme for further application and scale up. Moreover, through the case--control component, we may identify nutritional or environmental risk factors, which will ultimately help the programme to design a preventative strategy against PKDL.
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